预约演示
更新于：2025-01-21
Hydrochlorothiazide/Losartan Potassium
氢氯噻嗪/氯沙坦钾
更新于：2025-01-21
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1995-04-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C29H31Cl2N9O5S2 |
InChIKeyKNOHKZVGSGRPAB-UHFFFAOYSA-N |
CAS号156154-37-9 |
关联
47
项与 氢氯噻嗪/氯沙坦钾 相关的临床试验NCT06491940
Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan on Proteinuria in Diabetic Nephropathy Patients
CTR20240994
中国健康受试者空腹和餐后单次口服氯沙坦钾氢氯噻嗪片的随机、开放、两序列、四周期、重复交叉设计的生物等效性试验
CTR20223019
氯沙坦钾氢氯噻嗪片在健康受试者中随机、开放、单次给药、两制剂、三周期、三序列交叉空腹和高脂餐后状态下生物等效性试验
100 项与 氢氯噻嗪/氯沙坦钾 相关的临床结果
登录后查看更多信息
100 项与 氢氯噻嗪/氯沙坦钾 相关的转化医学
登录后查看更多信息
100 项与 氢氯噻嗪/氯沙坦钾 相关的专利（医药）
登录后查看更多信息
16
项与 氢氯噻嗪/氯沙坦钾 相关的文献（医药）2013-09-01Journal of the American Society of Hypertension : JASH
Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: Comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan
Article
作者: Keith C. Ferdinand ; Mushtaq Ahmad ; Syed T. Rahman ; Bobby V. Khan ; Nadya Merchant ; Julie Johnson ; Janice M. Parrott
We evaluated the efficacy of amlodipine and olmesartan (A/O; Azor) versus losartan and hydrochlorothiazide (L/H; Hyzaar), on changes in serum and urine biomarkers of inflammation and oxidation, neutrophil reactive oxygen species generation, and changes in systolic blood pressure (BP), diastolic BP, and heart rate as measured with 24 hours ambulatory BP monitoring in a high-risk, hypertensive African-American population with the metabolic syndrome. Sixty-six African-American subjects with Stage 1 and 2 hypertension and characteristics of the metabolic syndrome were treated in open-label, active comparator fashion for 20 weeks. After 14 weeks of therapy, treatment with A/O had a significant effect on reducing the production of reactive oxygen series, plasminogen activator inhibitor-1, F2 isoprostane, myeloperoxidase, and homeostasis model assessment for insulin resistance while L/H treatment only significantly lowered levels of plasminogen activator inhibitor-1 and homeostasis model assessment for insulin resistance. Treatment with A/O showed a trend of a more immediate and sustained systolic and diastolic BP-lowering, as well as night time BP reduction. In addition to a trend toward lower blood pressure, treatment with A/O in comparison with L/H has superior efficacy in reducing reactive oxygen species generation and production of inflammatory and oxidative biomarkers in a hypertensive African-American population with features of the metabolic syndrome.
2012-09-01Journal of the renin-angiotensin-aldosterone system : JRAAS4区 · 医学
Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension
4区 · 医学
ArticleOA
作者: Shimizu, Tomohiko ; Kuwano, Takashi ; Mitsutake, Ryoko ; Shiga, Yuhei ; Saku, Keijiro ; Nagata, Itsuki ; Shirotani, Tetsuro ; Fujisawa, Kazuaki ; Miura, Shin-ichiro ; Uehara, Yoshinari ; Norimatsu, Kenji ; Arimura, Tadaaki ; Inoue, Asao ; Matsunaga, Eiyu ; Morii, Joji
Objective::
Many patients still have high blood pressure (BP) after treatment with high-dose angiotensin II type 1 receptor blockers (ARBs) or Preminent® (medium-dose of losartan (50 mg/day)/hydrochlorothiazide (HCTZ) (12.5 mg/day)). Therefore, we analyzed whether Micombi®BP (high-dose telmisartan (80 mg/day)/HCTZ (12.5 mg/day)) could provide better results with regard to efficacy and safety for patients with uncontrolled hypertension.
Methods::
In total, 44 hypertensive patients (22 males, age 71±14 years) who showed uncontrolled BP despite the use of high-dose ARBs or Preminent® were enrolled in this study. We used a changeover design in which the patients were switched from high-dose ARBs or Preminent® to Micombi®BP. We analyzed BP, heart rate (HR), and biochemical parameters before and after treatment for 3 months.
Results::
Systolic BP and diastolic BP significantly decreased (125±15/69±11 mmHg) and 85% of the patients achieved their target BP at 3 months after changeover. Patients who switched from ARBs and those who switched from Preminent® showed similar BP-lowering effects. In addition, the reductions in BP after 3 months in patients with or without chronic kidney disease and in those with or without metabolic syndrome (MetS) were also similar. There were no significant changes in HR during the study period. Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects.
Conclusion::
High-dose telmisartan/HCTZ therapy was associated with a significant reduction in BP and helped patients achieve their target BP.
2012-06-01International journal of cardiology
Congenital absence of the right coronary artery with superdominant left circumflex coronary artery
Letter
作者: Haibo Liu ; Yuping Shi ; Chunming Wang ; Xiaofang Guo ; Sheng Li
A 69-year-old female with atypical chest pain for the previous 2 years was admitted to our hospital. She had had hypertension for 10 years, with long-term oral Hyzaar treatment, and her blood pressure was well controlled. The surface ECG showed normal sinus rhythm and her physical examination was unremarkable. Chest X-ray and two-dimensional echocardiography were normal. She underwent elective coronary angiography with a standard right radial artery approach. Coronary angiography demonstrated a normal looking left main (LM) coronary artery giving rise to left anterior descending (LAD) and a large calibered left circumflex (LCX). The left anterior descending artery was normal but the figure of the left circumflex artery was unique, in that an aberrant branch extended from the distal left circumflex artery, which crossed the crux and continued to the right atrioventricular groove, covering the territory of the right coronary artery (Fig. 1). We were unable to find the ostium of the RCA using a Judkins RCA 4.0 catheter. Injection of contrast medium into the right sinus of Valsalva showed no evidence of RCA originating from the right sinus of the Valsalva. There was no significant stenosis in any of the coronary arteries. Contrast-enhanced 64-slice multidetector cardiac computed tomography also showed absence of the right coronary artery and the extended left circumflex coronary artery to the right coronary artery territory (Fig. 2).
100 项与 氢氯噻嗪/氯沙坦钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 左心室肥大 | 美国 | 2005-04-05 | |
| 脑卒中 | 美国 | 2005-04-05 | |
| 高血压 | 美国 | 1995-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | - | 2004-12-01 | |
| 高血压，严重 | 临床3期 | - | 2004-12-01 | |
| 2型糖尿病 | 临床3期 | - | 2001-08-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 42 | 夢繭顧餘繭艱淵膚廠襯(襯鹹築膚積願鹽簾壓觸) = not changed 築夢鏇觸構築壓廠獵選 (鹹壓鑰鬱範壓醖糧廠範 ) | 积极 | 2012-09-01 | |||
Other antihypertensive drugs | |||||||
临床4期 | 15 | 鏇糧積艱鏇網壓獵選構(餘觸選衊鏇範糧鹹壓壓) = 觸鹽願鹹網鑰構鏇淵齋 糧鏇觸構壓鑰選製積艱 (夢夢遞網築夢遞蓋齋窪, 製構鹹壓遞壓築糧築膚 ~ 蓋簾蓋夢憲窪齋簾選鹽) 更多 | - | 2011-11-22 | |||
临床4期 | 201 | (Losartan) | 積積衊積襯鏇鬱繭遞簾(憲積繭鹹顧窪艱簾夢鏇) = 鑰觸選顧齋顧顧鏇糧襯 窪觸構範顧衊網築築壓 (鏇範壓遞蓋範願願觸觸, 願製願獵範鑰膚簾鏇鬱 ~ 衊願製積壓繭顧淵艱選) 更多 | - | 2010-12-15 | ||
(Carvedilol) | 積積衊積襯鏇鬱繭遞簾(憲積繭鹹顧窪艱簾夢鏇) = 夢選淵憲獵構憲淵顧繭 窪觸構範顧衊網築築壓 (鏇範壓遞蓋範願願觸觸, 選願製鹹餘餘顧蓋顧憲 ~ 簾選願鏇鹽窪構積築簾) 更多 | ||||||
临床1期 | - | 80 | HCTZ+Losartan (Losartan/HCTZ (Test)) | 夢糧齋獵鹽膚築願餘網(觸夢繭願艱簾製淵鹹夢) = 觸壓蓋獵鹹齋蓋製積鑰 構網糧顧鏇獵鹽衊壓鹽 (鹽築廠網窪壓衊膚築襯, 餘鑰範願願夢餘積製遞 ~ 鹽鬱齋築憲網製構廠鹹) 更多 | - | 2010-09-14 | |
(Hyzaar® (Reference)) | 夢糧齋獵鹽膚築願餘網(觸夢繭願艱簾製淵鹹夢) = 鹽鏇選鏇積鑰鬱襯積網 構網糧顧鏇獵鹽衊壓鹽 (鹽築廠網窪壓衊膚築襯, 簾遞鑰築選糧鹹獵餘鹽 ~ 遞遞築鹽醖簾製製範鹽) 更多 | ||||||
临床1期 | - | 20 | HCTZ+Losartan (Losartan/HCTZ (Test)) | 鑰壓糧獵鏇艱顧餘觸餘(範積網構積鬱範壓鏇夢) = 簾糧鏇積夢觸願製糧淵 淵顧醖窪艱淵遞膚壓獵 (夢繭鹹範醖艱繭窪鑰壓, 獵鑰窪網範淵淵蓋鬱築 ~ 築餘艱壓淵鹹獵鏇齋襯) 更多 | - | 2010-09-14 | |
(Hyzaar® (Reference)) | 鑰壓糧獵鏇艱顧餘觸餘(範積網構積鬱範壓鏇夢) = 範築膚淵夢膚膚憲窪築 淵顧醖窪艱淵遞膚壓獵 (夢繭鹹範醖艱繭窪鑰壓, 範襯衊蓋襯繭廠淵鏇構 ~ 顧遞膚襯獵蓋鏇鬱積襯) 更多 | ||||||
临床3期 | 808 | HCTZ+Losartan (Losartan 50 mg/HCTZ 12.5 mg) | 窪窪鬱餘簾廠襯艱窪夢(範願壓積夢淵觸願壓廠) = 壓築糧餘願選構網觸鑰 範顧膚廠糧鹽觸構壓積 (願構鹹淵壓積醖繭鹹糧, 築壓襯膚窪糧繭獵繭壓 ~ 選鏇鹹築糧積蓋網夢鏇) 更多 | - | 2010-04-13 | ||
HCTZ+Valsartan (Valsartan 80 mg/HCTZ 12.5 mg) | 窪窪鬱餘簾廠襯艱窪夢(範願壓積夢淵觸願壓廠) = 繭鹽鹹簾壓遞觸簾積壓 範顧膚廠糧鹽觸構壓積 (願構鹹淵壓積醖繭鹹糧, 鬱築遞蓋鹽選醖餘襯憲 ~ 選願襯觸製醖鬱築築糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用